OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
2.020
-0.100 (-4.72%)
Jan 22, 2025, 12:57 PM EST - Market open
OncoCyte Employees
As of December 31, 2023, OncoCyte had 46 total employees, including 43 full-time and 3 part-time employees. The number of employees decreased by 30 or -39.47% compared to the previous year.
Employees
46
Change (1Y)
-30
Growth (1Y)
-39.47%
Revenue / Employee
$15,413
Profits / Employee
-$948,043
Market Cap
34.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
OCX News
- 14 days ago - Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - GlobeNewsWire
- 15 days ago - Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - GlobeNewsWire
- 2 months ago - OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 - GlobeNewsWire
- 3 months ago - Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles - GlobeNewsWire
- 5 months ago - OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move - GlobeNewsWire
- 8 months ago - Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine - GlobeNewsWire